skip to Main Content
 

Three Quick Facts: Unilever, AstraZeneca and Bellway

*

Three things you need to know in the financial markets today from investment writer, Tony Cross.

#1. Unilever revenue growth eclipses margin erosion

Full year results from Unilever [LON:ULVR] are out today, showing that the company made solid progress despite the deteriorating macroeconomic climate. Revenues are up 9% and although increased costs have eroded margins by 230bps, profitability is still ahead, too. Management believe the picture of strong growth will be repeated in 2023, with sales growth heading towards 5% and costs savings plans allowing margins to be maintained. Some EUR5.8 billion was returned to shareholders during the year.

#2. AstraZeneca’s disappointing Q4 overshadowed by strong year of sales growth

AstraZeneca [LON:AZN] also has Q4 and full year numbers out today. Revenues are some 19% ahead for 2022 and although the last quarter was disappointing, management see this as something of a blip. 2023 is set to see another year of double digit revenue growth excluding COVID medicines and the company remains committed to its R&D pipeline.

#3. Bellway: sluggish market sees reservation rates tumble

Home builder Bellway [LON:BWY] has a trading update out today, covering the six months to 31st January. Completions are essentially flat year on year but reservation rates are down by a third and selling prices have barely budged. Regardless, the company is bullish with regards to its outlook even if the forward order book is reducing. Right now it stands at 5100 homes worth almost £1.4bn against last year’s figure of 6,600 homes worth close on £2bn.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top